NERVGEN PHARMA CORP (NGEN.CA) Stock Cash Flow
TSX-V:NGEN - TSX Venture Exchange - CA64082X2032 - Common Stock - Currency: CAD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -24.01M | -22.38M | -20.72M | -12.73M | -11.19M | |||
| Depreciation Amortization | 83.80K | 145.00K | 115.10K | 42.60K | 39.70K | |||
| Change In Working Capital | 838.60K | -240.40K | 2.12M | 430.50K | 1.41M | |||
| Interest Paid | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Taxes Paid | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other non cash items | 6.24M | 11.18M | 708.00K | 3.98M | 3.43M | |||
| OPERATING CASH FLOW | -16.84M | -11.30M | -17.78M | -8.27M | -6.31M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | 0.00 | -141.40K | -21.10K | -45.10K | -3.40K | |||
| Other Investing Activity | 58.90K | 2.60K | N/A | N/A | N/A | |||
| INVESTING CASH FLOW | 58.90K | -138.90K | -21.10K | -45.10K | -3.40K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -100.90K | -100.90K | -75.70K | N/A | N/A | |||
| Stock Issued/Repurchased | 24.43M | 867.20K | 22.85M | 21.28M | 9.02M | |||
| Other Financing Activity | -1.63M | N/A | -129.00K | -1.67M | -1.17M | |||
| FINANCING CASH FLOW | 22.70M | 766.30K | 22.64M | 19.61M | 7.85M | |||
| Exchange Rate Effect | -305.00K | -123.90K | 686.60K | 31.40K | -46.80K | |||
| CHANGE IN CASH | 5.61M | -10.79M | 5.52M | 11.33M | 1.49M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -16.84M | -11.30M | -17.78M | -8.27M | -6.31M | |||
| Capital Expenditure | 0.00 | -141.40K | -21.10K | -45.10K | -3.40K | |||
| FREE CASH FLOW | -16.84M | -11.44M | -17.81M | -8.31M | -6.31M | |||
All data in CAD